Given its ability to reduce cholesterol levels, some have wondered why. Review authors identified 23 studies that evaluated the effects of the PCSK9 inhibitors, alirocumab and evolocumab, in people at high risk of CVD. This meta-analysis aimed at investigating the safety and efficacy of treatment with the clinically available anti-PCSK9 monoclonal antibodies (mAbs) in all published randomized … While it's suggested berberine lowers blood sugar by increasing the number of insulin receptors on cells (exercise does this too), it's likely there are other … Berberine: Natural PCSK9 Inhibitor? Review authors identified the studies included in this review through electronic literature searches conducted up to December 2019. Relevant papers were identified from a search of PubMed/Medline and the Cochrane Central Register of Controlled Trials (CENTRAL). The therapy with proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors efficiently reduces plasma cholesterol levels, which has been recently associated with improvement in cardiovascular outcomes. Two PCSK9 inhibitors, alirocumab and evolocumab, have been approved to treat hypercholesterolemia and are available in the United States and the European Union. Studies were conducted in outpatient clinics. This review, which highlights a few of the recent advances in small-molecule PCSK9 inhibitors, is a witness to the growing interest for and importance of this field. Citrus Bergamot has also been shown to lower cholesterol. Watch on my Youtube channel if you prefer. PCSK9 inhibitors are given by subcutaneous (under the skin) injection, via self-administration with a pen device, one or two times per month. Although trials with PCSK9 inhibitors have not shown any alteration in plasma C-reactive protein levels, there is accumulating evidence showing lessened inflammatory response in the arterial wall that could attenuate atherosclerotic plaque development beyond the established LDL-lowering effect of PCSK9 inhibition. I. Dicembrini, S. Giannini, B. Ragghianti, E. Mannucci, M. Monami, Effects of PCSK9 inhibitors on LDL cholesterol, cardiovascular morbidity and all-cause mortality: a systematic review and meta-analysis of randomized controlled trials, Journal of Endocrinological Investigation, 10.1007/s40618-019-01019-4, (2019). This is an update of the review first published in 2017. Areas covered: This article reviews the available data on the effect of PCSK9 inhibitors on CV outcomes. PCSK9 Inhibitors. Jeffrey Geske, MD: Greetings.I'm Dr Jeff Geske, an assistant professor of medicine cardiologist at Mayo Clinic. Video Review. PCSK9 inhibitors are a new class of agents that are becoming increasingly important in the treatment to reduce LDL-C levels.